BTLA and nonpapillary renal cell carcinoma: The expression of immune checkpoint inhibitors, such as CD274 (PD-L1), CD276, TIGIT, PDCD1 (PD-1), LAG3, HAVCR2, CTLA4, and BTLA, was compared between the high-SGOL1-expression and low-SGOL1-expression groups of ccRCC patients, and the results suggested that immune checkpoint inhibitor expression was significant and highly expressed in the high-SGOL1-expression group.